Alpha Profiles · Company Profile

Immatics N.V.

https://registry.alpha.ac/companies/immatics-n-v

Entity: Public listing published
Primary listing: NASDAQ: IMTX
Verification: Partially verified
Last reviewed: 2026-10-21T04:46:05.46+00:00

Overview

Immatics N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing T-cell receptor (TCR) based immunotherapies aimed at combating cancer, primarily within the United States. Its therapeutic strategy centers on targeted immunotherapies for solid tumors, utilizing two distinct approaches: adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. The company's ACTengine™ portfolio features several candidates in Phase I clinical trials.

Governance leadership

Boards & Committees

Board and committee assignments appear only when the canonical public projection retains a current role and supporting source. Unpublished records are not interpreted as absence.

Record as of Oct 21, 2026. Chair, executive office, Lead Independent Director and committee appointments retain their separate source roles. A complete board composition denominator and committee charters are not established by a partial roster.

Board roles

0 public records

Board roster coverage is NOT_ASSERTED. An empty list is not evidence that this company has no board.

Source record

Alpha canonical company public projection

Supports Company identity, Published leadership, Entity status boundary

Reviewed 2026-10-21T04:46:05.46+00:00